Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 14/20 | 0.64 |
| ▸ | PRKCB | P05771 | 13/20 | 0.64 |
| ▸ | PRKCA | P17252 | 13/20 | 0.64 |
| ▸ | PRKCG | P05129 | 12/20 | 0.64 |
| ▸ | PRKCD | Q05655 | 6/20 | 0.64 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.64 |
| ▸ | PRKCZ | Q05513 | 3/20 | 0.64 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.40 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.38 |
| ▸ | IDH1 | O75874 | 1/20 | 0.37 |
| ▸ | MAT2A | P31153 | 3/20 | 0.37 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5754128 | 0.85 | PRKCA (0.85) | GSK3BPRKCBPRKCAPRKCGPRKCD | |
| SCHEMBL5757880 | 0.82 | PRKCA (0.85) | GSK3BPRKCBPRKCAPRKCGPRKCD | |
| SCHEMBL5758197 | 0.81 | GSK3B (0.64) | GSK3BPRKCBPRKCAPRKCGPRKCD | |
| SCHEMBL13013272 | 0.78 | GSK3B (1.00) | GSK3BPRKCBPRKCAPRKCGPRKCD | |
| SCHEMBL3771437 | 0.78 | PRKCA (0.84) | GSK3BPRKCBPRKCAPRKCGPRKCD | |
| SCHEMBL5757844 | 0.77 | GSK3B (0.67) | GSK3BPRKCBPRKCAPRKCGPRKCD | |
| SCHEMBL3784374 | 0.77 | PRKCA (0.76) | GSK3BPRKCBPRKCAPRKCGPRKCD | |
| SCHEMBL3771589 | 0.76 | PRKCA (0.84) | GSK3BPRKCBPRKCAPRKCGPRKCD | |
| SCHEMBL3779533 | 0.75 | PRKCA (0.64) | GSK3BPRKCBPRKCAPRKCGPRKCD | |
| SCHEMBL5757325 | 0.75 | GSK3B (0.83) | GSK3BPRKCBPRKCAPRKCGPRKCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7855203-B2 | Indazolyl-substituted pyrroline compounds as kinase inhibitors | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC. (US) | 2010-12-21 | — | — | US | disclosed |
| US-20080096949-A1 | Indazolyl-substituted pyrroline compounds as kinase inhibitors | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC. | 2008-04-24 | — | — | US | disclosed |
| US-7329657-B2 | Indazolyl-substituted pyrroline compounds as kinase inhibitors | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2008-02-12 | — | — | US | disclosed |
| US-7304060-B2 | Indazolyl-substituted pyrroline compounds as kinase inhibitors | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2007-12-04 | — | — | US | disclosed |
| EP-1362047-B1 | INDAZOLYL-SUBSTITUTED PYRROLINE COMPOUNDS AS KINASE INHIBITORS | ORTHO MCNEIL PHARM INC (US) | 2006-05-17 | — | — | EP | disclosed |
| US-6849643-B2 | Indazolyl-substituted pyrroline compounds as kinase inhibitors | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2005-02-01 | — | — | US | disclosed |
| US-20050004202-A1 | Indazolyl-substituted pyrroline compounds as kinase inhibitors | ZHANG HAN-CHENG (US) | 2005-01-06 | — | — | US | disclosed |
| US-20040259928-A1 | Indazolyl-substituted pyrroline compounds as kinase inhibitors | ZHANG HAN-CHENG (US) | 2004-12-23 | — | — | US | disclosed |
| US-20030055097-A1 | Indazolyl-substituted pyrroline compounds as kinase inhibitors | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096949-A1 | Indazolyl-substituted pyrroline compounds as kinase inhibitors | MAP2K2, MAP3K20, MAP2K3 | GSK3B 601/4885PRKCB 40/4885PRKCA 43/4885 |
| US-20040259928-A1 | Indazolyl-substituted pyrroline compounds as kinase inhibitors | MAP2K2, MAP3K20, MAP3K1 | GSK3B 587/4885PRKCB 51/4885PRKCA 53/4885 |
| US-20030055097-A1 | Indazolyl-substituted pyrroline compounds as kinase inhibitors | MAP2K2, MAP3K20, MAP3K1 | GSK3B 587/4885PRKCB 51/4885PRKCA 53/4885 |
| US-20050004202-A1 | Indazolyl-substituted pyrroline compounds as kinase inhibitors | MAP2K2, MAP3K20, MAP2K3 | GSK3B 601/4885PRKCB 40/4885PRKCA 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.